An 8-week course of Harvoni Cost for hepatitis C virus

May 3rd, 2019
Not a member of Pastebin yet? Sign Up, it unlocks many cool features!
  1. An 8-week course of Harvoni for hepatitis C virus infection in both black and nonblack patients was a cost-effective alternative to a 12-week course, according to researchers.
  3. Shorter course therapy may be a viable option under a constrained budget and can benefit patients who are treatment-naive and noncirrhotic, they wrote in Open Forum Infectious Diseases.
  5. “While highly efficacious therapies can cure HCV with few side effects in as little at 8 weeks, many individuals and payers are struggling with the cost,” researcher Jake R. Morgan, PhD, of Boston Medical Center, and colleagues wrote. “For [Harvoni (ledipasvir/sofosbuvir, Gilead Sciences)], our results indicate that 8-week therapy is cost-effective and can result in better population outcomes in both black and nonblack patients compared with 12-week therapy, even with lower rates of SVR.”
  7. The researchers noted that DAAs, although very effective, are expensive. Shortening the course of treatment from 12 weeks to 8 weeks can significantly lower costs, they said, but shorter courses may be ineffective in black patients and those with HIV coinfection, among other factors.
  9. A newly FDA-approved 8-week regimen — Mavyret (glecaprevir/pibrentasvir, AbbVie) — is choice for some physicians, but many payers still prefer ledipasvir/sofosbuvir based on negotiated prices, according to the researchers.
  11. “Understanding the trade-offs between cost and efficacy for 8- and 12-week treatment courses is critical,” they said.
  13. In a simulation model — called the Hepatitis C Cost-Effectiveness Model — researchers examined the economic value associated with 8- and 12-week treatment courses of ledipasvir/sofosbuvir.
  15. They found that treating eligible patients — treatment-naive, noncirrhotic, and with HCV RNA of less than 6 million copies — with 8-week courses under a fixed budget constraint was cost-effective and increased the number of both black and nonblack patients who achieved SVR by roughly 50% compared with the 12-week regimen.
  17. Although shorter courses resulted in more treatment failures, resources invested in extending therapy to 12 weeks “would likely be more productively invested in other HCV-related health care interventions, such as expanding HCV screening or improving HCV linkage to care,” the researchers said.
  19. Morgan and colleagues also evaluated the cost-effectiveness of testing patients for resistance to NS5A inhibitors.
  21. “We found that NS5A testing was cost-effective as long as the SVR rate for 8 weeks of therapy in patients with [resistance-associated substitutions] conferring more than 100-fold resistance to ledipasvir was 88% or less,” they wrote.
  23. .....................................................
  25. Address
  27. Shop No. 1 Plot No. 12, Shopping Complex, Karam Pura, New Delhi – 110015
  29. Contact
  31. Anand Pratap Singh
  33. +91-9999344593
  35. E-mail
  37. Info@medixocentre.com
  39. Web
  41. https://www.medixocentre.com/
RAW Paste Data